American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Business

Will the Airbus share price rebound after the A320 recall?

by admin December 1, 2025
December 1, 2025
Will the Airbus share price rebound after the A320 recall?

Airbus share price moved sideways as investors assessed the impact of last week’s recall of its most important jet. AIR was trading at €204, down by 5.35% from its highest point this year. So, will the Airbus A320 recall crash the stock?

Airbus A320 recall

The main catalyst for the Airbus stock price is a major recall of the popular A320 model last week. In a statement, the company ordered over 6,000 A320 planes to make a software upgrade to fix an error of intense solar radiation, which had the ability to corrupt data critical to the functioning of flight controls.

The crisis started when a JetBlue plane experienced an uncommanded and limited pitch-down event. Fortunately, no customer was hurt and the plane landed in a nearby airport.

This recall happened in one of the worst periods, especially in the United States, as millions of people traveled for the Thanksgiving holiday.

Still, the recall will likely have no major impact on Airbus and its operations. For one, reports show that many airlines have conducted the upgrades and restarted flying. In a statement, American Airlines said that all aircraft impacted by the issue have now been fixed.

Other airlines have also reported the fix, with the most notable ones being Air India, Jetstar, and Virgin Australia.

Additionally, historically, product recalls, especially such limited ones, have a limited impact on companies.

Airbus business is doing well 

The new crisis at Airbus came as its business is facing several key headwinds, which it revealed in the last financial results.

The company said that its order intake plunged by 20.7% in the first nine months of the year to 514, while its orderbook slipped by 1% to 8,665.

Its helicopter and defense businesses also had lower order books than in the same period last year. The defense orders dropped by 38.4% to 6,753, while its helicopter orders fell by 0.6% to 306.

Still, despite this, its huge backlog helped to ensure that its revenue growth was relatively strong, with the revenue figure moving from €44.4 billion in the first nine months of 2024 to €47.4 billion. It also secured big orders at the Dubai Airshow.

Most of this revenue was from the Airbus brand, which accounts for 70% of sales. It made €33.4 billion in revenues, with its adjusted EBIT rising to €3.2 billion.

Airbus also grew its profitability, with the adjusted EBIT coming in at €4.1 billion from the €2.8 billion it made in the same period last year. One reason for this growth is that the company reduced some of its costs, with R&D budget falling from €2.4 billion to €2.1 billion.

The company is facing some notable headwinds, including the fact that Boeing starting to regain its market share, helped by 737, 777x and 787 Dreamliner.

Airbus share price technical analysis 

Airbus stock chart | Source: TradingView

The daily timeframe chart shows that the Airbus stock price has been in an uptrend this year as investors reacted to its robust demand and improvement in its supply chain issues.

Airbus stock has rebounded from the year-to-date low of €123.62 in April to the current €204. 

While the stock has pulled back recently, it remains above the 100-day Exponential Moving Average (EMA). It has also formed a bullish flag pattern, which is made up of a vertical line and a descending channel.

The stock seems to be forming a double-top pattern whose upper side is at €217, and the neckline is at €200. 

Therefore, the stock will likely continue rising as bulls target the upper side of the double-top pattern at €217. A move above that level will point to more gains, potentially to €250. 

The post Will the Airbus share price rebound after the A320 recall? appeared first on Invezz

0
FacebookTwitterGoogle +Pinterest
previous post
South Korea cyber crisis deepens as Coupang data leak exposes national vulnerabilities
next post
Wockhardt jump 13% as US FDA accepts NDA for Zaynich antibiotic in key milestone for Indian pharma

Related Posts

AGMH stock price rally on 6-K filing is...

September 20, 2025

SoFi plans crypto comeback within 6 months, says...

April 30, 2025

Oracle stock price forecast: brace for a brief...

October 27, 2024

RollS-Royce share price forecast: extremely bullish above 810p

May 7, 2025

Five ETFs to invest in to hedge against...

February 9, 2025

GLD ETF analysis: is this gold fund on...

August 7, 2025

Airbnb bans indoor security cameras for properties listed...

March 13, 2024

Will the BT Group share price bull run...

August 26, 2025

Oracle, OpenAI, SoftBank plan $500B AI infrastructure deal...

January 22, 2025

Trump win boosts Musk’s fortune by $70 billion...

November 12, 2024

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • Commodity wrap: silver hits new record high, dwarfing gold’s rise; oil prices up post CME outage chaos

      November 30, 2025
    • Intel stock jumps as tech analyst says Apple may tap its foundry for future M-series chips

      November 30, 2025
    • Europe bulletin: markets slip, UK-EU defense rift, Wingtech escalates chip dispute

      November 30, 2025
    • Starbucks faces pressure as workers escalate strike across 120 stores ahead of Black Friday

      November 30, 2025
    • Wall Street close: Nasdaq extends rally to five days as markets eye Fed rate cut

      November 30, 2025

    Categories

    • Business (4,660)
    • Investing (3,102)
    • Latest News (2,117)
    • Politics (1,541)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved